Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa

Nature Communications

Volumn 5, Issue , 2014, Pages

  Gerberry, David J ^a,c   Wagner, Bradley G ^a   Garcia Lerma, J Gerardo ^b   Heneine, Walid ^b   Blower, Sally ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c XAVIER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

DISEASE INCIDENCE; DISEASE TRANSMISSION; EPIDEMIC; GEOGRAPHICAL VARIATION; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; OPTIMIZATION; PUBLIC HEALTH;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; EPIDEMIC; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL GEOGRAPHY; PRE-EXPOSURE PROPHYLAXIS; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; VIRUS TRANSMISSION; HEALTH CARE ORGANIZATION; HIV INFECTIONS; MALE; PREVALENCE; PROCEDURES; SEX RATIO; THEORETICAL MODEL; TRANSMISSION;

SUB-SAHARAN AFRICA;

AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; FEMALE; HEALTH CARE RATIONING; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MODELS, THEORETICAL; PRE-EXPOSURE PROPHYLAXIS; PREVALENCE; SEX DISTRIBUTION;

EID: 84922569866     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6454     Document Type: Article

References (40)

1. UNAIDS. UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf (2013).
2. Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl. J. Med. 363, 2587-2599 (2010).
3. Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New Engl. J. Med. 367, 399-410 (2012).
4. Thigpen, M. C. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New Engl. J. Med. 367, 423-434 (2012).
5. Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
6. Cohen, M. S. et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl. J. Med. 365, 493-505 (2011).
7. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf (2013).
8. WHO. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://apps.who.int/iris/bitstream/10665/104264/1/9789241506830-eng.pdf (2014).
9. Abdool Karim, Q. et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 12, 67 (2011).
10. Sani, A. & Kroese, D. P. Controlling the number of HIV infectives in a mobile population. Math. Biosci. 213, 103-112 (2008).
11. Paltiel, A. D. et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin. Infect. Dis. 48, 806-815 (2009).
12. Walensky, R. P. et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin. Infect. Dis. 54, 1504-1513 (2012).
13. Schackman, B. R. & Eggman, A. A. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Curr. Opin. HIV AIDS 7, 587-592 (2012).
14. Walensky, R. P. et al. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J. Acquir. Immune Defic. Syndr. 56, 26-35 (2011).
15. Coburn, B. J., Okano, J. T. & Blower, S. Current drivers and geographic patterns in Lesotho: implications for treatment and prevention in Sub-Saharan Africa. BMC Med. 11, 224 (2013).
16. Coburn, B. J. & Blower, S. Mapping HIV epidemics in sub-Saharan Africa with use of GPS data. Lancet Global Health 1, e251-e253 (2013).
17. Kandala, N.-B., Campbell, E. K., Rakgoasi, S. D., Madi-Segwagwe, B. C. & Fako, T. T. The geography of HIV/AIDS prevalence rates in Botswana. HIV AIDS (Auckl) 4, 95-102 (2012).
18. Napierala Mavedzenge, S., Olson, R., Doyle, A. M., Changalucha, J. & Ross, D. A. The epidemiology of HIV among young people in sub-Saharan Africa: know your local epidemic and its implications for prevention. J. Adolesc. Health 49, 559-567 (2011).
19. Hethcote, H. W. & Yorke, J. A. Gonorrhea transmission dynamics and control (Lecture Notes in Biomathematics, vol. 66). Biom. J. 28, 304 (1984).
20. Lasry, A., Sansom, S. L., Hicks, K. A. & Uzunangelov, V. A model for allocating CDC's HIV prevention resources in the United States. Health Care Manag. Sci. 14, 115-124 (2011).
21. Halloran, M. E., Longini, I. M., Nizam, A. & Yang, Y. Containing bioterrorist smallpox. Science 298, 1428-1432 (2002).
22. Coburn, B. J. & Blower, S. A feasibility analysis of implementing interventions for discordant couples in 14 African countries: implications for epidemic control. AIDS 26, 1969-1971 (2012).
23. Smith, J. M. et al. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc. Natl Acad. Sci. USA 110, 16145-16150 (2013).
24. Romano, J. et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retroviruses 25, 483-488 (2009).
25. Andrews, C. D. et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 343, 1151-1154 (2014).
26. Radzio, J. S. W. et al. Monthly GSK744 long-acting injections protect macaques against repeated vaginal SHIV exposures (Conference on Retroviruses and Opportunistic Infections) Abstact 40 LB (2014).
27. Andrews, J., Wood, R., Bekker, L., Middlekoop, K. & Walensky, R. P. Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care. J. Infect. Dis. 206, 543-551 (2012).
28. Wilson, D. P., Kahn, J. & Blower, S. Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urbanrural divide. Proc. Natl Acad. Sci. USA 103, 14228-14233 (2006).
29. Abu-Raddad, L. J. et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3, e2230 (2008).
30. Celum, C., Levine, R., Weaver, M. & Wald, A. Genital herpes and human immunodeficiency virus: double trouble. Bull. World Health Organ. 82, 447-453 (2004).
31. Corey, L. Synergistic copathogens-HIV-1 and HSV-2. N. Engl. J. Med. 356, 854-856 (2007).
32. Freedman, E. & Mindel, A. Epidemiology of herpes and HIV co-infection. J. HIV Ther. 9, 4-8 (2004).
33. Barnabas, R. V., Webb, E. L., Weiss, H. A. & Wasserheit, J. N. The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis. AIDS 25, 1559-1573 (2011).
34. Freeman, E. E. et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20, 73-83 (2006).
35. Wald, A. & Link, K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J. Infect. Dis. 185, 45-52 (2002).
36. Blower, S. & Dowlatabadi, H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int. Stat. Rev. 62, 229-243 (1994).
37. Johnson, L. F., Alkema, L. & Dorrington, R. E. A Bayesian approach to uncertainty analysis of sexually transmitted infection models. Sex. Transm. Infect. 86, 169-174 (2010).
38. Smith, R. J., Okano, J. T., Kahn, J. S., Bodine, E. N. & Blower, S. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 327, 697-701 (2010).
39. AIDS Committee of the Actuarial Sociey of South Africa. Actuarial Society of South Africa AIDS and Demographic Model. http://aids.actuarialsociety.org.za/ASSA2008-Model-3480.htm (2011).
40. Supervie, V., Garca-Lerma, J. G., Heneine, W. & Blower, S. HIV, transmitted drug resistance, and the paradox of pre-exposure prophylaxis. Proc. Natl Acad. Sci. USA 107, 12381-12386 (2010).